Rodman & Renshaw on Amylin: Why does AMLN Takeover Chatter Always Come Before Slow Bydureon Rx Figures? (AMLN)

Amylin Pharmaceuticals (NASDAQ:AMLN) is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. The company is particularly focused on the therapeutic potential of new peptide hormone drug candidates and the creation of novel and groundbreaking therapies for the treatment of diabetes, obesity, and other metabolic diseases.

Rodman & Renshaw has issued a report on Amylin, assigning it a Market Underperform / Speculative Risk rating and a $22 Target Price.

Analyst Michael G. King, Kr writes,

"Overall, this week’s report appears to be as disappointing as last week’s was encouraging. Last week’s report showed gains across the board for AMLN and the GLP-1 class. This week those gains were given back, and AMLN products were hit harder than Victoza. Additionally, we pulled the weekly Rx statistics from Victoza two years ago (Figure 3 and Table 5). Despite the GLP-1 market growing some 20% in the two years since the launch of Victoza, the absolute NRx generated by Bydureon is almost half that achieved by Victoza at the same point in the respective launches."

Read the full report below.

Rodman Renshaw on Amylin Pharma 5 21-12

View more documents from DailyDoseEquities.

Rodman & Renshaw on Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. The company is particularly focused on the therapeutic potential of new peptide hormone drug candidates and the creation of novel and groundbreaking therapies for the treatment of diabetes, obesity, and other metabolic diseases.

Rodman & Renshaw has released a report on Amylin, assigning it a Market Underperform/Speculative Risk with a $22 target price. 

Analyst Michael G. King writes, 

"We maintain our Market Underperform rating and a $22 target. We continue to believe our skepticism is justified given the company’s history of poor execution and the most recent quarter’s fair-to-middling (in our opinion) results. We continue to believe the exenatide franchise is unwanted by those who already have a presence in the diabetes space and a sub-optimal set of assets for those companies to gain a presence in the diabetes/metabolic disease space. In our opinion, AMLN management would have done well to accept the BMY offer of $22 per share; justifying our price target on the shares."

Read the full report below.  

Rodman renshaw report on amln 5 14-12

View more documents from DailyDoseEquities